Gilead Sciences (GILD) Revenue — Quarter Ended Mar 31, 2026
Revenue declined compared to the immediately preceding quarter but rose relative to the same quarter one year earlier. The trailing twelve-month revenue remained substantial.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue declined compared to the immediately preceding quarter but rose relative to the same quarter one year earlier. The trailing twelve-month revenue remained substantial.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$7B
Revenue reported for this quarter.
Quarter-over-quarter
-12.2%
Change from the immediately preceding quarter.
Year-over-year
+4.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$29.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $7.1B | +1.8% |
| Sep 30, 2025 | $7.8B | +3.0% |
| Dec 31, 2025 | $7.9B | +4.7% |
| Mar 31, 2026 | $7B | +4.4% |
Revenue performance
Cash from operations improved during the quarter, supported by strong product sales collections.
Quarterly comparison
Quarterly revenue decreased from the prior quarter yet increased from the prior year's same period, reflecting a mixed sequential and annual trend.
What to watch
Ongoing investment in research and development and pipeline progression remains a key focus.